TY - JOUR T1 - SARS-CoV-2 induces human endogenous retrovirus type W envelope protein expression in blood lymphocytes and in tissues of COVID-19 patients JF - medRxiv DO - 10.1101/2022.01.18.21266111 SP - 2022.01.18.21266111 AU - Benjamin Charvet AU - Joanna Brunel AU - Justine Pierquin AU - Mathieu Iampietro AU - Didier Decimo AU - Nelly Queruel AU - Alexandre Lucas AU - María del Mar Encabo-Berzosa AU - Izaskun Arenaz AU - Tania Perez Marmolejo AU - Francina Valezka Bolaños Morales AU - Arturo Ivan Gonzalez Gonzalez AU - Armando Castorena Maldonado AU - César Luna Rivero AU - Cyrille Mathieu AU - Patrick Küry AU - Jose Flores-Rivera AU - Santiago Avila Rios AU - Gonzalo Salgado Montes de Oca AU - Jon Schoorlemmer AU - Branka Horvat AU - Hervé Perron Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/18/2022.01.18.21266111.abstract N2 - Patients with COVID-19 may develop abnormal inflammatory response and lymphopenia, followed in some cases by delayed-onset syndromes, often long-lasting after the initial SARS-CoV-2 infection. As viral infections may activate human endogenous retroviral elements (HERV), we studied the effect of SARS-CoV-2 on HERV-W and HERV-K envelope (ENV) expression, known to be involved in immunological and neurological pathogenesis of human diseases. Our results have showed that the exposure to SARS-CoV-2 virus activates early HERV-W and K transcription but only HERV-W ENV protein expression, in an infection- and ACE2-independent way within peripheral blood mononuclear cell cultures from one-third of healthy donors. Moreover, HERV-W ENV protein was significantly increased in serum and plasma of COVID-19 patients, correlating with its expression in CD3+ lymphocytes and with disease severity. Finally, HERV-W ENV was found expressed in post-mortem tissues of lungs, heart, brain olfactory bulb and nasal mucosa from acute COVID-19 patients in cell-types relevant for COVID-19-associated pathogenesis within affected organs, but different from those expressing of SARS-CoV-2 antigens. Altogether, the present study revealed that SARS-CoV-2 can induce HERV-W ENV expression in cells from individuals with symptomatic and severe COVID-19. Our data suggest that HERV-W ENV is likely to be involved in pathogenic features underlying symptoms of acute and post-acute COVID. It highlights the importance to further understand patients‘ genetic susceptibility to HERV-W activation and the relevance of this pathogenic element as a prognostic marker and a therapeutic target in COVID-19 associated syndromes.Competing Interest StatementHP, BC, JB, JP, NQ received compensation for their work from Geneuro Innovation (France) Funding StatementThis study was funded by the french National Agency for Researsch (ANR) - program RA-COVID-19 V15 (project name : COVERI)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:- Ethics committee/IRB of SECRETARIA DE SALUD INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS ISMAEL COSIO VILLEGAS (MEXICO)gave ethical approval for this work - Ethics committee/IRB of HOSPICES CIVILS DE LYON (HCL)/ BIOBANK OF CROIX ROUSSE HOSPITAL (FRANCE) gave ethical approval for this work - Ethics committee/IRB of SERVICIOS CIENTIFICO TECNICOS - SERVICIO DE BIOBANCO (BSSA)OF UNIVERSITY OF SARAGOZA (SPAIN) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript ER -